StockNews.com lowered shares of Innoviva (NASDAQ:INVA – Free Report) from a buy rating to a hold rating in a report published on Thursday. Innoviva Price Performance Shares of INVA opened at $18.08 on ...

Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and critical care ...

Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and ...

Sales of Trelegy Ellipta and Flixotide/Flovent surged 17% and 47%, respectively. Sales of Advair/Seretide and Anoro Ellipta fell 2% each. Revlar/Breo Ellipta sales declined 5%. The decline in ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks Consensus Estimate of 53 cents. Core earnings declined 20% year over year ...

Its biggest competitor is GSK, which also has a new dual bronchodilator Anoro Ellipta. Results from GSK's combination have underwhelmed until now, and failed to show superiority to the older ...